Plain-English translation of NCT06636617 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing a new radioactive medication called 177Lu-JH04 in patients with advanced cancers that have a specific protein marker (FAP) on their tumor cells. The medication is designed to find and attack cancer cells while sparing healthy tissue. Researchers want to understand how safe the medication is, how it moves through the body, and whether it helps shrink tumors.
Many patients with advanced cancer run out of standard treatment options. This medication targets a protein that is found on more than 90% of cancers but rarely on healthy cells, making it a potentially safer way to deliver cancer-fighting radiation directly to tumors.
You likely qualify if…
You likely don't qualify if…
You will receive a single injection of the medication through an IV. The trial is testing three different dose levels, and you will receive one of them. Your doctors will then monitor you closely with scans and blood tests to measure how much radiation reaches your tumors, check for any side effects, and see whether the cancer responds to the treatment.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
China